Dr. Reddy's Laboratories Ltd ADR (RDY)

$79.8

+0.6

(+0.76%)▲

Market is closed - opens 7 PM, 18 Oct 2024

Performance

  • $78.90
    $79.80
    $79.80
    downward going graph

    1.13%

    Downside

    Day's Volatility :1.13%

    Upside

    0.0%

    downward going graph
  • $63.72
    $84.46
    $79.80
    downward going graph

    20.15%

    Downside

    52 Weeks Volatility :24.56%

    Upside

    5.52%

    downward going graph

Returns

PeriodDr. Reddy's Laboratories Ltd.Sector (Health Care)Index (Russel 2000)
3 Months
0.64%
1.8%
0.0%
6 Months
11.06%
10.7%
0.0%
1 Year
19.42%
17.0%
0.0%
3 Years
22.51%
19.8%
-21.9%

Highlights

Market Capitalization
13.2B
Book Value
$1769.05
Dividend Share
40.0
Dividend Yield
0.6%
Earnings Per Share (EPS)
3.97
PE Ratio
19.92
PEG Ratio
4.55
Wall Street Target Price
85.62
Profit Margin
19.26%
Operating Margin TTM
23.39%
Return On Assets TTM
10.93%
Return On Equity TTM
20.59%
Revenue TTM
288.5B
Revenue Per Share TTM
289.4
Quarterly Revenue Growth YOY
13.900000000000002%
Gross Profit TTM
113.8B
EBITDA
79.5B
Diluted Eps TTM
3.97
Quarterly Earnings Growth YOY
-0.01
EPS Estimate Current Year
3.79
EPS Estimate Next Year
3.97
EPS Estimate Current Quarter
0.93
EPS Estimate Next Quarter
0.96

Analyst Recommendation

Buy
    42%Buy
    30%Hold
    27%Sell
Based on 40 Wall street analysts offering stock ratings for Dr. Reddy's Laboratories Ltd.(by analysts ranked 0 to 5 stars)
Based on 40 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
11
18
Hold
12
13
11
Sell
11
16
12

Analyst Forecast

What analysts predicted

Upside of 7.29%

Current $79.80
Target $85.62

Company Financials

FY19Y/Y Change
Revenue
2.2B
↑ 8.32%
Net Income
269.6M
↑ 91.67%
Net Profit Margin
12.22%
↑ 5.32%
FY20Y/Y Change
Revenue
2.3B
↑ 13.49%
Net Income
261.4M
↑ 3.74%
Net Profit Margin
11.17%
↓ 1.05%
FY21Y/Y Change
Revenue
2.6B
↑ 8.66%
Net Income
236.7M
↓ 11.59%
Net Profit Margin
9.09%
↓ 2.08%
FY22Y/Y Change
Revenue
2.8B
↑ 13.0%
Net Income
309.2M
↑ 36.72%
Net Profit Margin
10.99%
↑ 1.9%
FY23Y/Y Change
Revenue
3.0B
↑ 14.69%
Net Income
548.0M
↑ 91.22%
Net Profit Margin
18.33%
↑ 7.34%
FY24Y/Y Change
Revenue
3.4B
↑ 13.54%
Net Income
670.6M
↑ 23.56%
Net Profit Margin
19.95%
↑ 1.62%
Q1 FY23Q/Q Change
Revenue
765.7M
↓ 6.99%
Net Income
116.6M
↓ 23.09%
Net Profit Margin
15.23%
↓ 3.19%
Q2 FY23Q/Q Change
Revenue
820.1M
↑ 7.01%
Net Income
170.7M
↑ 46.22%
Net Profit Margin
20.81%
↑ 5.58%
Q3 FY23Q/Q Change
Revenue
828.4M
↑ 2.1%
Net Income
178.2M
↑ 5.53%
Net Profit Margin
21.51%
↑ 0.7%
Q4 FY23Q/Q Change
Revenue
866.6M
↑ 4.86%
Net Income
165.6M
↓ 6.83%
Net Profit Margin
19.11%
↓ 2.4%
Q1 FY24Q/Q Change
Revenue
924.0M
↑ 6.35%
Net Income
167.6M
↑ 0.95%
Net Profit Margin
18.14%
↓ 0.97%
Q2 FY24Q/Q Change
Revenue
919.1M
↑ 0.0%
Net Income
166.8M
↑ 0.0%
Net Profit Margin
18.14%
↑ 0.0%
FY19Y/Y Change
Total Assets
3.2B
↓ 0.08%
Total Liabilities
1.2B
↓ 14.03%
FY20Y/Y Change
Total Assets
3.1B
↑ 3.02%
Total Liabilities
1.0B
↓ 9.36%
FY21Y/Y Change
Total Assets
3.6B
↑ 14.32%
Total Liabilities
1.2B
↑ 17.16%
FY22Y/Y Change
Total Assets
3.9B
↑ 11.74%
Total Liabilities
1.4B
↑ 17.25%
FY23Y/Y Change
Total Assets
3.9B
↑ 8.83%
Total Liabilities
1.1B
↓ 15.21%
FY24Y/Y Change
Total Assets
4.7B
↑ 20.03%
Total Liabilities
1.3B
↑ 18.87%
Q1 FY23Q/Q Change
Total Assets
3.9B
↑ 4.38%
Total Liabilities
1.1B
↑ 72.9%
Q2 FY23Q/Q Change
Total Assets
4.1B
↑ 3.78%
Total Liabilities
673.8M
↓ 38.48%
Q3 FY23Q/Q Change
Total Assets
4.2B
↑ 3.58%
Total Liabilities
1.1B
↑ 69.67%
Q4 FY23Q/Q Change
Total Assets
4.5B
↑ 7.44%
Total Liabilities
1.3B
↑ 11.77%
Q1 FY24Q/Q Change
Total Assets
5.0B
↑ 11.39%
Total Liabilities
1.5B
↑ 14.93%
Q2 FY24Q/Q Change
Total Assets
5.0B
↑ 0.0%
Total Liabilities
1.4B
↑ 0.0%
FY19Y/Y Change
Operating Cash Flow
411.8M
↑ 59.21%
Investing Cash Flow
-110.9M
↓ 48.08%
Financing Cash Flow
-306.0M
↑ 380.32%
FY20Y/Y Change
Operating Cash Flow
400.0M
↑ 3.96%
Investing Cash Flow
-66.0M
↓ 36.29%
Financing Cash Flow
-337.2M
↑ 17.97%
FY21Y/Y Change
Operating Cash Flow
490.2M
↑ 19.64%
Investing Cash Flow
-311.1M
↑ 360.29%
Financing Cash Flow
-4.1M
↓ 98.82%
FY22Y/Y Change
Operating Cash Flow
368.8M
↓ 21.27%
Investing Cash Flow
-346.2M
↑ 16.45%
Financing Cash Flow
-31.8M
↑ 712.75%
FY23Y/Y Change
Operating Cash Flow
715.9M
↑ 109.45%
Investing Cash Flow
-503.1M
↑ 56.79%
Financing Cash Flow
-326.6M
↑ 1009.04%
Q1 FY23Q/Q Change
Operating Cash Flow
239.3M
↓ 15.4%
Investing Cash Flow
-503.1M
↑ 61.61%
Financing Cash Flow
-52.3M
↓ 837.22%
Q2 FY23Q/Q Change
Operating Cash Flow
136.9M
↓ 42.83%
Investing Cash Flow
-55.0M
↓ 89.08%
Financing Cash Flow
-18.0M
↓ 65.66%
Q3 FY23Q/Q Change
Operating Cash Flow
215.8M
↑ 59.34%
Investing Cash Flow
-153.6M
↑ 182.33%
Financing Cash Flow
-84.7M
↑ 376.69%

Technicals Summary

Sell

Neutral

Buy

Dr. Reddy's Laboratories Ltd. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
-0.41%
11.06%
19.42%
22.51%
108.92%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-3.24%
-11.17%
3.64%
13.78%
22.2%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-4.88%
24.91%
21.46%
36.71%
36.71%
Zoetis Inc.
Zoetis Inc.
-0.65%
27.97%
11.58%
-4.09%
51.35%
Viatris Inc.
Viatris Inc.
0.0%
6.49%
25.34%
-12.38%
-27.66%
Catalent, Inc.
Catalent, Inc.
-0.12%
7.72%
31.87%
-53.77%
21.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
19.92
19.92
4.55
3.79
0.21
0.11
0.01
1769.05
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
35.65
35.65
0.26
4.59
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
32.32
32.32
1.49
0.39
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
38.13
38.13
2.66
5.83
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.67
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
3.04
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
Buy
$13.2B
108.92%
19.92
19.26%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$12.0B
22.2%
35.65
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$45.3B
36.71%
32.32
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$88.1B
51.35%
38.13
26.29%
Viatris Inc.
Viatris Inc.
Hold
$14.1B
-27.66%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$10.9B
21.21%
211.02
-23.81%

Insights on Dr. Reddy's Laboratories Ltd.

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 62.96B → 76.72B (in $), with an average increase of 3.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 13.78B → 13.92B (in $), with an average increase of 0.5% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 31.9% return, outperforming this stock by 12.5%

Institutional Holdings

  • Robeco Institutional Asset Management BV

    1.24%

  • Royal Bank of Canada

    1.23%

  • Morgan Stanley - Brokerage Accounts

    1.22%

  • Renaissance Technologies Corp

    1.20%

  • BlackRock Inc

    1.08%

  • Aikya Investment Management Ltd

    0.83%

Corporate Announcements

  • Dr. Reddy's Laboratories Ltd. Dividends December,2024

    In the quarter ending December,2024. Dr. Reddy's Laboratories Ltd. has declared dividend of $0.48

    Read More

Company Information

Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, Telangana, India. Founded in 1984 by Dr. K. Anji Reddy, the company provides a wide range of pharmaceuticals in India and over 25 countries worldwide. Dr. Reddy's Laboratories operates in various segments, including generic medicines, active pharmaceutical ingredients (APIs), custom pharmaceutical services, biosimilars, and differentiated formulations. The company's portfolio includes products for therapeutic areas such as gastroenterology, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's Laboratories is listed on the NYSE under the ticker symbol RDY, making its American Depositary Receipts (ADRs) available to U.S. investors. Known for its commitment to innovation, quality, and affordability, Dr. Reddy's Laboratories continues to deliver comprehensive healthcare solutions and improve the lives of patients globally. Currently Dr. Reddy's Laboratories ADR has a market cap of $13.73 Billion. It has a P.E ratio of 0.0. The shares of Dr. Reddy's Laboratories ADR are trading at $79.2 .

Organization
Dr. Reddy's Laboratories Ltd.
Employees
27048
CEO
Mr. Gunupati Venkateswara Prasad B.E.
Industry
Health Technology

Discover More

FAQs